But these were originally developed to treat diabetes
Triple-Agonist Mechanism of Action GLP-1 Pathway (Glucagon-Like Peptide-1) Activates receptors in the hypothalamus to reduce appetite, stimulates insulin secretion from pancreatic beta cells, and slows gastric emptying
whether a higher dose is right for you is a decision made with your doctor
for semaglutide, liraglutide and dulaglutide, no dose adjustment is generally required, but monitor in severe renal impairment, especially with gastrointestinal losses Pregnancy and breastfeeding: GLP-1 therapies are not recommended during pregnancy
It plays a critical role in cellular energy production, mitochondrial function, DNA repair, metabolism, and overall cellular health and longevity